DE3853758T2 - Heterozyklische Spiroverbindungen und ihre Herstellung. - Google Patents

Heterozyklische Spiroverbindungen und ihre Herstellung.

Info

Publication number
DE3853758T2
DE3853758T2 DE3853758T DE3853758T DE3853758T2 DE 3853758 T2 DE3853758 T2 DE 3853758T2 DE 3853758 T DE3853758 T DE 3853758T DE 3853758 T DE3853758 T DE 3853758T DE 3853758 T2 DE3853758 T2 DE 3853758T2
Authority
DE
Germany
Prior art keywords
group
atom
formula
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3853758T
Other languages
German (de)
English (en)
Other versions
DE3853758D1 (de
Inventor
Masatomi Harada
Hitoshi Nagaoka
Toshinari Tamura
Shin-Ichi Tsukamoto
Shinji Usuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3853758D1 publication Critical patent/DE3853758D1/de
Publication of DE3853758T2 publication Critical patent/DE3853758T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE3853758T 1987-10-05 1988-09-30 Heterozyklische Spiroverbindungen und ihre Herstellung. Expired - Lifetime DE3853758T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25210487 1987-10-05
JP28629787 1987-11-12
JP8432788 1988-04-05

Publications (2)

Publication Number Publication Date
DE3853758D1 DE3853758D1 (de) 1995-06-14
DE3853758T2 true DE3853758T2 (de) 1995-09-07

Family

ID=27304516

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3853758T Expired - Lifetime DE3853758T2 (de) 1987-10-05 1988-09-30 Heterozyklische Spiroverbindungen und ihre Herstellung.

Country Status (14)

Country Link
US (4) US4940795A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0311313B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0236183A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970007947B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1036653C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE122353T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU621559B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1337817C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3853758T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK554288A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2074441T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3016995T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU211687A9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO171109C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412096A (en) * 1987-10-05 1995-05-02 Yamanouchi Pharmaceutical Co., Ltd. Hydrochloride salts of heterocyclic spiro compounds
ES2074441T3 (es) * 1987-10-05 1995-09-16 Yamanouchi Pharma Co Ltd Compuestos espiro heterociclicos y su preparacion.
US5594000A (en) * 1989-06-21 1997-01-14 Astra Ab Spirofurane derivatives
US5075317A (en) * 1989-06-21 1991-12-24 Fisons Corporation Spirofurane derivatives
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5407938A (en) * 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE914238A1 (en) * 1990-12-19 1992-07-01 Fisons Corp Novel spirofurane derivatives
WO1992020683A1 (en) * 1991-05-15 1992-11-26 Yamanouchi Pharmaceutical Co., Ltd. (-)-(s)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4,5]decane l-tartrate
CA2154569A1 (en) * 1993-01-28 1994-08-04 Jeffrey J. Hale Spiro-substituted azacycles as tachykinin receptor antagonists
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
JP2983141B2 (ja) * 1993-10-06 1999-11-29 株式会社三和化学研究所 新規化合物及び該化合物を有効成分とする脳機能改善剤
CA2289578A1 (en) 1997-05-30 1998-12-03 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
AU7509200A (en) * 1999-08-13 2001-03-13 Aventis Cropscience Gmbh Heterocyclic spiro compounds as pesticides
WO2001078709A2 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
JP2003063964A (ja) * 2001-08-28 2003-03-05 Senju Pharmaceut Co Ltd ドライアイまたはドライアイを伴なう疾病の予防治療剤
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
EP1917964A4 (en) * 2005-07-26 2009-11-11 Senju Pharma Co PERCUTANE RESORBIBLE OPHTHALMIC PREPARATION
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
EP2076288A2 (en) * 2006-09-22 2009-07-08 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
KR101122469B1 (ko) 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
KR101675174B1 (ko) * 2009-01-26 2016-11-10 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
US9034891B2 (en) 2009-01-26 2015-05-19 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10017736B2 (en) 2012-07-13 2018-07-10 Pain Therapeutics, Inc. Method of inhibiting tau phosphorylation
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019232077A1 (en) 2018-05-29 2019-12-05 Chrono Therapeutics Inc. Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
CN115124545B (zh) * 2022-08-31 2023-01-03 南京远淑医药科技有限公司 一种促性腺激素释放激素受体拮抗剂中间体的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3305556A (en) * 1962-11-23 1967-02-21 Pfizer & Co C Novel hypoglycemic agents
NL124853C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1963-07-19
SU335944A1 (ru) * 1970-12-15 1976-01-25 Научно-исследовательский институт химии Саратовского государственного университета им.Н.Г.Чернышевского Способ получени соединений р да 1-окса6-азаспиро(4,4)нонана
GB1301254A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1971-07-08 1972-12-29
US3784551A (en) * 1971-07-08 1974-01-08 Yoshitomi Pharmaceutical 2-oxo-1,4-dioxa-8-azaspiro (4.5) decanes and related compounds
US3839273A (en) * 1971-11-13 1974-10-01 Sankyo Co N-substituted piperidine derivatives, process for preparing the same and their use as stabilizers
SU434735A1 (ru) * 1972-03-01 1975-12-15 Научно-исследовательский институт химии Саратовского государственного университета им.Н.Г.Чернышевского Способ получени 7-метил-(или 2,7диметил)-2-метокси- -пропионитрил1-окса-6-азаспиро-(4,4)-нонана
SU465399A1 (ru) * 1973-07-19 1975-03-30 Научно-исследовательский институт химии при Саратовском государственном университете им.Н.Г.Чернышевского Способ получени натриевых солей 2-метокси- -карбоксиэтил-1-окса6-азаспиро-(4,4)-нонана
IL48452A (en) * 1975-11-11 1979-07-25 Purdue Frederick Co Spiro (1,3-dioxolane-4,3') quinuclidines,their preparationand pharmaceutical compositions comprising them
US4321379A (en) * 1981-01-28 1982-03-23 American Cyanamid Company 4-Aryl-1-oxa-8-azaspiro[4,5]dec-3-en-2-ones
SU1002294A1 (ru) * 1981-08-14 1983-03-07 Ордена Трудового Красного Знамени Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2,2-Диалкил-3-тиа-8-азаспиро/5,5/ундеканы
EP0189370A3 (de) * 1985-01-16 1988-01-27 Sandoz Ag Spiro-dioxolane, -dithiolane und -oxothiolane
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4981858A (en) * 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
ES2074441T3 (es) * 1987-10-05 1995-09-16 Yamanouchi Pharma Co Ltd Compuestos espiro heterociclicos y su preparacion.
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents

Also Published As

Publication number Publication date
USRE34653E (en) 1994-07-05
NO171109B (no) 1992-10-19
AU621559B2 (en) 1992-03-19
ES2074441T3 (es) 1995-09-16
EP0311313A2 (en) 1989-04-12
AU2344988A (en) 1989-04-06
JPH0544948B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-07-07
NO171109C (no) 1993-01-27
NO884406L (no) 1989-04-06
US5041549A (en) 1991-08-20
EP0311313B1 (en) 1995-05-10
KR970007947B1 (ko) 1997-05-19
US4996210A (en) 1991-02-26
CN1033629A (zh) 1989-07-05
JPH0236183A (ja) 1990-02-06
KR890006649A (ko) 1989-06-15
DE3853758D1 (de) 1995-06-14
DK554288D0 (da) 1988-10-04
EP0311313A3 (en) 1990-12-05
US4940795A (en) 1990-07-10
CA1337817C (en) 1995-12-26
ATE122353T1 (de) 1995-05-15
NO884406D0 (no) 1988-10-04
DK554288A (da) 1989-05-26
GR3016995T3 (en) 1995-11-30
HU211687A9 (en) 1995-12-28
CN1036653C (zh) 1997-12-10

Similar Documents

Publication Publication Date Title
DE3853758T2 (de) Heterozyklische Spiroverbindungen und ihre Herstellung.
DE69034146T2 (de) Chemische Verbindungen
DE69217945T2 (de) Azanorbornanderivate
DE3789039T2 (de) Verbrückte bicyclische N-heterocyclische Verbindungen.
DE69125099T2 (de) Indolderivate
DE69220258T2 (de) Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
DE69630772T2 (de) Neue polycyclische aminopyridine als acetylcholinesterase hemmer, verfahren zur herstellung und deren verwendung
DE69612003T2 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
DE69130683T2 (de) PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL
DE69922494T2 (de) Zyklische n-acylamin-derivate
US5412096A (en) Hydrochloride salts of heterocyclic spiro compounds
US4992436A (en) Spiro-azabicyclic muscarinic agonists
US5324723A (en) Oxazoles and thiazoles for the treatment of senile dementia
DE19601938A1 (de) Neue Phosphodiesteraseinhibitoren
EP0085899B1 (de) Neue Pyridobenzodiazepinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0085892B1 (de) Substituierte Dibenzodiazepinone, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE2628570B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0086982A1 (de) Substituierte Thienobenzodiazepinone, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
CH556837A (de) Verfahren zur herstellung neuer spiroindanpyrrolidinderivate.
DE69007904T2 (de) 1-Oxa-2-oxo-8-azaspiro[4,5]decan-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus.
CH625789A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE69001794T2 (de) Phenothiazinderivate, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DE68907845T2 (de) Verbrückte bicyclische 4-(4-(3-Benzisothiazolyl)-1-piperazinyl)-butylimide mit antipsychotischer Wirkung.
DE68922596T2 (de) 3-(3-Ethyl-1,2,4-oxadiazol-5-yl)-1-azabicycloheptan, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen.
DE60212153T2 (de) Tetrahydropyranderivate und ihre verwendung als therapeutika

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP